787590 Re-excision following breast conservation surgery in modern times: A single institution's quality study looking at re-excision following segmental mastectomy at both the institutional and individual surgeon level



Katherine Kopkash, MD, Shale Mack, Kristine Kuchta, MS, Catherine Pesce, MD, Lawrence Krause, MD, David Winchester, MD, Ermilo Barrera, MD, Katharine Yao, MD

Department of Surgery, NorthShore University HealthSystem



PURPOSE

- Breast conservation is performed in the majority of breast cancer patients in the United States and re-excision is a known risk with wide variability in the published rates.
- We performed a single institution quality study which looked at our current re-excision rates, both as an institution and individually as surgeons, and the associated factors.

METHODS

- Our institution has 6 breast surgeons and is an accredited breast center. We performed a retrospective chart review of patients undergoing a segmental mastectomy (CPT code 19301) from 2016-2018.
- Re-excision was defined as return to the operating room for either another segmental mastectomy or full mastectomy within 90 days.
- Patient characteristics, tumor histology, imaging findings, and neoadjuvant treatment were recorded. Individual surgeon re-excision rates were reported for each year and compared to re-excision rates generated by the tumor registry and reported to each surgeon.
- Prior to seeing their individual rates, each surgeon was asked to estimate their reexcision rate, report factors associated with re-excisions, and whether re-excision rates should be a quality measure.

RESULTS

 1,508 segmental mastectomies (CPT code 19301) were completed during the studied time frame and 238 re-excisions were performed (on 205 patients), with an overall institutional re-excision rate of 15.8%.

RESULTS

Characteristics of Re-excision patients 2016-2018

	N (%)
TOTAL PATIENTS	205
AGE [Mean ± SD]	63.2 ± 11.7
CANCER TYPE PRE-OP	
DCIS	71 (34.6)
IDC	89 (43.4)
ILC	24 (11.7)
Other	21 (10.2)
RESIDUAL TYPE OF CANCER POST-OP	
DCIS	64 (31.2)
IDC	98 (47.8)
ILC	29 (14.2)
Other	14 (6.8)
SIZE IN SITU DISEASE (N=64)	
< 2.0 cm	17 (26.6)
2.0-3.9 cm	26 (40.6)
≥ 4.0 cm	20 (31.3)
Unknown	1 (1.6)
SIZE INVASIVE DISEASE (N=141)	
< 2.0 cm	91 (64.5)
2.0-3.9 cm	31 (22.0)
≥ 4.0 cm	14 (9.9)
Unknown	5 (3.6)
DISTANCE FROM MARGIN IN-SITU DISEASE (N=64)	
< 1 mm	32 (50.0)
≥ 1.0 mm	8 (12.5)
Involved	24 (37.5)

DISTANCE FROM MARGIN INVASIVE DISEASE (N=141)	
< 1 mm	25 (17.7)
≥ 1.0 mm	37 (26.2)
Involved	73 (51.8)
Unknown	6 (4.3)
NEOADJUVANT CHEMOTHERAPY	3 (1.5)
PRE-OPERATIVE MRI	55 (26.8)
TYPE OF LOCALIZATION	
Wire	45 (22.0)
Seed	133 (64.9)
US in OR	3 (1.5)
Unknown	24 (11.7)
TYPE OF SUBSEQUENT SURGERY	
Re-excision	143 (69.8)
Mastectomy	23 (11.2)
Multiple Re-excisions	15 (7.3)
Re-excision(s) followed by Mastectomy	23 (11.2)
Re-excision followed by Mastectomy and Re-	
excision	1 (0.5)
NUMBER OF RE-EXCISIONS	
1	167 (81.5)
2	30 (14.6)
3	8 (3.9)

RESULTS

- Cancer was found in the re-excision specimens in 53.4% of re-excision cases. The re-excision rates for 2016, 2017, and 2018 were 16.2%, 15.1%, and 16.0% respectively. The re-excision rate varied significantly between surgeons, ranging from 3.3% to 30.0% overall from 2016-2018.
- Patients with ductal carcinoma in situ (DCIS), particularly a larger size of DCIS, were more likely to require re-excision (p <0.0001).
- The tumor registry reported an overall re-excision rate of 20.7% compared to the chart review re-excision rate of 15.8%.
- All six surgeons underestimated their re-excision rate by 4.2% on average, with the underestimation varying from 0.6-8.3%. None of the surgeons felt that margins are an accurate metric of quality in regards to breast cancer surgeries.

CONCLUSIONS

- Despite the margin guidelines, reexcision rates following breast conservation surgery vary widely by breast surgeon within a single institution and using different methodology to calculate re-excision rates.
- Institutions considering a re-excision quality study should take these factors into account.

Corresponding author: Katherine Kopkash MD, kkopkash@northshore.org